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Abstract
Fusarium species are primarily plant pathogens that occasionally cause human disease. Several 
members of this genus of molds have caused widespread destruction of food crops. Fusarium 
species are found primarily in soli and on decaying vegetable matter, but also occur in water. 
Localized infections, such as keratitis, sinusitis, and skin and nail infections, occur in immu-
nocompetent persons. However, invasive sinusitis and pulmonary infection, as well as wide-
spread dissemination, are the rule in markedly immunosuppressed patients, especially those 
who are profoundly neutropenic. The acute onset of painful skin lesions and the growth of a 
mold in blood cultures are clues to disseminated fusariosis in immunosuppressed patients. The 
organism grows readily in the laboratory, but identification to the species level is difficult. 
Biopsy of infected tissues shows acutely branching septate hyphae that are often indistinguish-
able from those of Aspergillus species. Localized lesions respond reasonably well to antifungal 
agents and surgical excision. Invasive pulmonary and disseminated infection respond poorly 
to antifungal therapy, in part because of the resistance of most species to many antifungal 
agents, but more importantly, to the absence of an effective host response. Most patients 
who have disseminated or invasive pulmonary infection are treated with a combination of 
voriconazole and a lipid formulation of amphotericin B, with the hope that at least one drug 
may have activity against the organism, and perhaps better killing can be achieved using two 
drugs. Unfortunately, patients who have disseminated fusariosis and who remain neutropenic 
rarely survive the infection, regardless of the therapy used.
© 2012 ACIN. Published by Elsevier España, S.L. All rights reserved.
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Introduction
Fusarium species are known primarily for their role as 
important plant pathogens that have caused devastat-
ing destruction of many fruits and vegetables. Human 
fusariosis varies in its manifestations from localized infec-
tions, such as keratitis, to intoxications that can occur 
with ingestion of contaminated foods, to devastating dis-
seminated infections that are seen primarily in markedly 
immunosuppressed patients. The organism exists world 
wide, with different species occupying different ecologi-
cal niches. A hallmark of Fusarium species is their marked 
resistance to currently available antifungal agents. We 
will review the epidemiology, clinical manifestations, and 
treatment options for fusariosis.
Organism
The genus Fusarium includes over a 100 species, very few of 
which are human pathogens. The most common species that 
infect humans are F. solani, F. oxysporum, F. moniliforme 
(F. verticillioides), and F. proliferatum. F. solani causes 
approximately 50% of human cases of fusariosis. Fusarium 
species are predominantly plant pathogens. Several of the 
species of Fusarium have destroyed certain varieties of food 
producing plants, such as bananas. They grow well in the 
soil and are found abundantly on decaying organic material. 
These molds are also present in water and cause infections 
of the gills, skin, and shells, of sharks, seals, and marine tur-
tles, respectively.
Fusarium species have small microconidia and large 
fusiform or banana-shaped macroconidia, explaining the 
genus name1. The macroconidia are distinctive and allow 
clinical laboratories to define the genus as Fusarium, but 
further identification to the species level is difficult and 
is often not routinely performed. Species identification is 
important for surveillance studies and for defining species-
dependent antifungal susceptibility patterns. Although 
antifungal susceptibility testing gives broad guidance to 
the choice of drugs, it is not standardized for this genus2. 
For patients with disseminated infection, correlation of in 
vitro susceptibility results with clinical outcomes is poor, 
most likely reflecting the poor immune status of patients 
with disseminated fusariosis.
Epidemiology
Fusarium species occur world wide but, at least for 
disseminated infection, most cases are reported from 
large cancer centers in warmer climates in the U.S. and 
Europe. In the last several decades, increasing reports 
of disseminated fusariosis have emerged among highly 
immunosuppressed patients, among whom the highest 
rates are in those who have a hematological malig-
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Resumen
Las distintas especies de Fusarium son principalmente patógenos de plantas que ocasional-
mente pueden originar enfermedades en humanos. Varios miembros de este género de hongos 
han causado una gran destrucción de cultivos alimentarios. Suelen haber especies de Fusarium 
en el suelo y en la materia vegetal en descomposición, pero también se pueden hallar en el 
agua. Algunas infecciones localizadas, como queratitis, sinusitis e infecciones en piel y uñas 
pueden afectar a personas inmunocompetentes. Sin embargo, las sinusitis invasoras y las 
infecciones pulmonares, de rápida diseminación, son habituales en pacientes muy inmunodep-
rimidos, especialmente en aquellos que son profundamente neutropénicos. El inicio agudo de 
lesiones dolorosas en la piel y el crecimiento de moho en cultivos sanguíneos son indicadores 
de una fusariosis diseminada en pacientes inmunodeprimidos. El organismo crece fácilmente 
en laboratorio, pero la identificación de la especie es complicada. Las biopsias de tejidos 
infectados muestran hifas septadas extremadamente ramificadas que a menudo son indistin-
guibles de las que presentan las especies de Aspergillus. Las lesiones localizadas responden 
razonablemente bien a agentes antifúngicos y a la cirugía. Las infecciones pulmonares inva-
soras y extendidas responden de manera deficitaria a la terapia antifúngica, en parte debido 
a la resistencia que presentan la mayoría de especies a muchos agentes antifúngicos, pero 
principalmente por la ausencia de una respuesta efectiva del huésped. La mayoría de los 
pacientes que tienen infección pulmonar invasoras o diseminada son tratados con una combi-
nación de voriconazol y una formulación lipídica de anfotericina B, con la esperanza de que al 
menos un fármaco actúe contra el patógeno y se alcancen mejores resultados con el uso de dos 
fármacos. Desgraciadamente, los pacientes que padecen una fusariosis diseminada y aquellos 
que permanecen neutropénicos, rara vez sobreviven a la infección, independientemente de 
la terapia utilizada.
© 2012 ACIN. Publicado por Elsevier España, S.L. Todos los derechos reservados.
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nancy and are neutropenic or have received an alloge-
neic hematopoietic cell transplant3-7. Reports from the 
U.S. have noted the highest concentrations of Fusarium 
species in the outside air during hotter, more humid 
months2. Although most cases of disseminated fusariosis 
are acquired from the outside environment, nosocomial 
acquisition of this organism related to construction has 
been documented8. Plants also have been implicated 
as a source for hospital-acquired infection, and for this 
reason, live plants are restricted on units in which immu-
nosuppressed patients are cared for. Additionally, there 
have been reports of hospital water sources, especially 
showers, yielding Fusarium species on culture9. Although 
firm proof that showers have been the source of the 
organism in specific patients is lacking, many transplant 
units do not allow patients to take showers.
Localized disease is most often related to direct inocu-
lation. This occurs in outdoor workers who experience 
inoculation of soil containing the organism into skin and 
subcutaneous tissues. Fusarial onychomycoses are presum-
ably also  initiated by local inoculation of organisms from 
either water or soil. One of the most devastating localized 
infections results from corneal inoculation by contami-
nated contact lenses, resulting in severe keratitis.
An outbreak of Fusarium keratitis among soft contact 
lens wearers in the U.S., Singapore, and Hong Kong from 
2004 to 2006 was traced back to a specific contact lens 
solution (ReNu with MoistureLoc) that was subsequently 
removed from the market10. The contact lens solution 
was not intrinsically contaminated, but had lost its usual 
antimicrobial properties and allowed the growth of several 
different species of Fusarium in the contact lens cases11. 
The organisms were introduced by the users themselves, 
presumably from their hands, and then persisted, most 
likely in a biofilm in the case and on the contact lens. 
Introduction of the contaminated lens onto the eye led to 
destructive keratitis, anterior chamber infection, exten-
sion into the vitreous in many cases, and loss of vision.
Pathogenesis
Fusarium species are angioinvasive, a property shared 
with Aspergillus species and the Mucorales. With invasion 
through blood vessels, hemorrhagic infarction and necrosis 
occur. When the conidia are inhaled from the environ-
ment, the lungs and the sinuses are primarily affected. 
This occurs almost entirely in markedly immunosuppressed 
patients who usually are neutropenic. The depth and 
length of the neutropenia are important predictors for the 
development of disseminated infection5,6. Neutrophils are 
essential for inhibiting hyphal growth, and macrophages 
can both phagocytize conidia and also attack hyphae. The 
use of corticosteroids is also a risk factor for development 
of disseminated infection.
Toxin-induced disease is now rare, but outbreaks have 
been described in the past in which persons ingesting 
grain contaminated with toxin-producing Fusarium species 
developed bone marrow suppression and death, so-called 
alimentary toxic aleukia. There is no evidence that the 
mycotoxins produced by Fusarium species contaminating 
grains play any role in invasive fusariosis.
Clinical manifestations
Localized Infections
Skin and Skin Structure Infections
Localized infection can follow after local inoculation of 
Fusarium species into skin or subcutaneous tissues12. In the 
tropics, eumycetoma has been reported due to F. solani or 
F. moniliforme, but overall, Fusarium species are not among 
the most common causes of eumycetoma. In immunocompe-
tent persons who have experienced trauma or who have burn 
wounds, cellulitis, ulcerative lesions, and abscesses due to 
fusariosis can occur. Solid organ transplant recipients tend to 
develop localized nodular or ulcerative lesions of the extrem-
ities, likely related to trauma, and not accompanied by dis-
semination4. There are no specific features in these skin and 
soft tissue infections that are distinctive for fusariosis.
Although Fusarium species are a less common cause of 
onychomycosis than dermatophytes, they are an increas-
ingly important cause of infection in immunosuppressed 
patients, especially those who are neutropenic13,14. In this 
population, onychomycosis may be the prelude to a painful 
paronychial infection and resultant cellulitis. Disseminated 
fusariosis has been reported secondary to Fusarium paro-
nychia in neutropenic patients12.
Keratitis
Corneal infection following trauma with introduction of 
plant material or soil or contamination of contact lenses, 
presents with pain, photophobia, tearing, and decreased 
visual acuity. The cornea becomes cloudy and may perfo-
rate. The infection often spreads into the anterior cham-
ber, and a hypopyon may be seen. In some cases, extension 
through the globe into the posterior chamber occurs, result-
ing in vitritis and retinal damage. Early diagnosis allowing 
aggressive treatment is imperative to retain vision.
Sinusitis
Fusarium species can cause chronic invasive sinusitis. This 
uncommon infection occurs in patients who are not immu-
nosuppressed but often are older and have underlying 
illnesses, such as diabetes15. This form of sinusitis slowly 
progresses over weeks to months, causing increasing pain 
and discharge from the nares, but it is not life threaten-
ing. Fungus ball formation, which almost always occurs in 
the maxillary sinus, is uncommonly due to Fusarium15.
In patients who are immunosuppressed, sinusitis due to 
Fusarium species is an aggressive infection with invasion 
into bone and adjacent structures of the face. Clinically, 
the patients present with the acute onset of fever, face 
pain, and discharge from the nares; necrosis of the pal-
ate or nasal turbinates is common because of the angio-
invasive nature of the mold. It is indistinguishable from 
infection with the Mucorales, such as Rhizopus and Mucor 
species, and Aspergillus species. Dissemination can occur 
secondary to an initial focus in the sinuses.
Other localized infections
Other manifestations of fusariosis include infections asso-
ciated with chronic peritoneal dialysis catheters, osteomy-
elitis, septic arthritis, and a variety of different visceral 
abscesses2.
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Pulmonary Infection
The lungs are frequently the primary site of infection 
with Fusarium species, which is not surprising given that 
inhalation of aerosolized conidia from the environment 
is a prime means of spread of these molds. Pneumonia 
is unusual in immunocompetent hosts, but must always 
be thought of in immunosuppressed hosts, especially 
those who have a hematological malignancy and who are 
neutropenic3,5. Symptoms and signs are similar to those 
seen with aspergillosis, which is more common. Symp-
toms include fever, cough, malaise, and dyspnea; pleu-
ritic chest pain and hemoptysis appear as the infection 
progresses.
Any symptoms suggesting pulmonary infection in an 
immunosuppressed host should trigger an immediate chest 
radiograph and computed tomography scan of the thorax. 
Classic findings on computed tomography scan include those 
seen with other angioinvasive molds and most commonly 
include multiple nodules of varying sizes, some of which 
may be surrounded by ground glass opacification signifying 
hemorrhage (so-called halo sign), and some of which may 
show cavitation3,16. Disease may remain localized to the 
lungs, but more commonly, the pulmonary findings are just 
one manifestation of disseminated fusariosis.
Disseminated Infection
Dissemination is the rule when Fusarium infection occurs 
in those who are immunosuppressed and especially in 
those who are neutropenic3,5. Suspicion for disseminated 
infection is raised when a patient who is febrile and 
appears severely ill develops painful skin lesions (Fig. 1). 
The lesions have been characterized by Nucci and Anais-
sie in their literature review of 232 immunocompromised 
patients who had fusariosis, 72% of whom developed 
cutaneous manifestations12. The lesions vary from papules 
to nodules, with or without central necrosis. They can 
appear as target lesions or classic ecthyma gangrenosum. 
Uncommonly, bullae and vesicles appear. The lesions are 
usually on the extremities, almost always multiple, and 
can become purpuric or hemorrhagic as they evolve. The 
crucial clue for the clinician is that these lesions are pain-
ful, in contrast to the non-painful lesions of candidiasis 
and aspergillosis.
Diagnosis
The diagnosis of fusariosis is established by growing the 
organism from a sterile body site. Frequently, a non-
sterile site, such as respiratory secretions or skin, is the 
source for culture, and for these patients, there must be 
a compatible clinical picture and/or radiological evidence 
typical for an invasive fungal infection. Fusarium is one of 
the few genera of molds that are able to sporulate in vivo. 
Because of this, they are capable of growing in blood cul-
ture bottles, and this may be the first hint that a patient 
has disseminated fusariosis6. This is a valuable clue for 
clinicians who usually think that a patient who has an 
invasive fungal pneumonia has aspergillosis. Aspergillosis is 
clearly much more common than fusariosis, but Aspergil-
lus species only very rarely can be isolated from blood 
culture bottles. Growing Fusarium from respiratory secre-
tions, including BAL fluid, in a patient who is immunosup-
pressed and has computed tomography findings suggestive 
of invasive mold infection is adequate to make a diagnosis 
of probable fusariosis and begin treatment immediately.
Histopathological examination of biopsy material from 
skin lesions or pulmonary infiltrates shows acutely branch-
ing septate hyphae that are indistinguishable from those of 
Aspergillus and Scedosporium species (Fig. 2). Cytological 
preparations from BAL fluid and scrapings from keratitis 
lesions show similar septate hyphae. Histopathology defines 
the extent of tissue invasion, but culture is needed to dif-
ferentiate the specific hyaline mold that is causing disease.
There are no antibody or antigen detection tests avail-
able to aid in diagnosis. PCR has been used in some 
cases using universal primers or genus-specific probes for 
Fusarium in BAL fluid, skin biopsy specimens, and ocular 
Figure 1 Skin lesions that developed acutely in a profoundly 
neutropenic woman who had received an allogeneic stem cell 
transplant 53 days before. The upper lesion was nodular and the lower 
one purpuric; both were painful.
Figure 2 Methenamine silver stain of the biopsy of one of the skin 
lesions from the patient shown in Figure 1. Acutely branching septate 
hyphae are scattered throughout the tissue.
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samples6. In situ hybridization has been reported to be 
useful to differentiate Fusarium from other hyaline molds 
in a small number of patients17.
Treatment
Localized Infections
Treatment of localized Fusarium infections of the skin and 
subcutaneous tissues is usually successful. If the infection 
progresses to become a mycetoma, treatment is more dif-
ficult, and surgery along with antifungal therapy is often 
required. Fusarium onychomycosis should be treated with 
systemic azole therapy. In immunosuppressed patients, 
especially those who have hematological malignancies and 
are neutropenic, onychomycosis should be treated as soon 
as possible by removing the nail and giving systemic anti-
fungal therapy, usually voriconazole (VOR).
The most difficult local infection to treat is keratitis; 
although the organism is eradicated, visual acuity often 
remains poor. The standard treatment for fungal keratitis 
has been topical natamycin, but this has not been effective 
in many cases of Fusarium infection. With extension into 
the chambers of the eye, systemic antifungal agents should 
be used, and most cases require a keratoplasty to remove 
the infected lens. Increasingly, VOR is used for fusariosis 
as well as other ocular fungal infections18. Topical VOR as 
well as oral VOR, at the doses noted below, are used. With 
extension into the vitreous body, intravitreal VOR is given in 
addition to systemic therapy.
Pulmonary and Disseminated Infections
Invasive Fusarium infections are exceedingly difficult to 
treat because most species are resistant to many anti-
fungal agents2. The most common species that infects 
humans, F. solani, is the most resistant. The most active 
drugs appear to be amphotericin B (AMB), VOR, and posa-
conazole (POS), but the minimum inhibitory concentration 
required to inhibit growth is higher than that noted for 
other molds, such as Aspergillus fumigatus. Fluconazole 
and itraconazole are not active against most Fusarium 
species, and echinocandins have no activity against Fusar-
ium species. In vitro, terbinafine has activity against some 
species and based on these data, has been used as an 
adjunct along with other agents, but it never should be 
used as monotherapy. In vitro susceptibility studies do not 
correlate well with outcomes of treatment, and the range 
of minimum inhibitory concentration values varies for dif-
ferent species and among different laboratories2.
In general, a lipid formulation of AMB, VOR, or POS is 
used for most patients who have disseminated infection 
or serious localized infection5,6,19-25. Many clinicians use 
dual therapy with a lipid formulation of AMB and VOR for 
patients who have disseminated infection22,24,25.
Amphotericin B is almost always given as a lipid for-
mulation (liposomal AMB or AMB lipid complex) so as to 
decrease the risk of nephrotoxicity and also to allow an 
increase in the daily dose. The dosages recommended are 
3-5 mg/kg daily, but in ill patients, doses as high as 10 
mg/kg daily have been used. One study noted a partial or 
complete response in 12 of 26 (46%) patients who received 
high dose AMB lipid complex23.
A retrospective review of 73 cases of invasive fusariosis 
treated with VOR found an overall partial or complete response 
in 34 (47%), most of whom had disseminated infection, and 
most of whom had received prior antifungal therapy21. The best 
response rate was seen in patients who were least immunosup-
pressed, which is not surprising; all patients who remained 
neutropenic throughout the course of therapy died.
Salvage therapy with POS has been shown effective 
for some patients. In one series, 10 of 21 (48%) patients 
achieved a complete or partial response with POS therapy 
after they had failed or developed intolerance to prior 
therapy. However, only 20% of leukemic patients with 
persistent neutropenia responded compared with 67% of 
leukemic patients whose neutropenia resolved20.
Case reports describing the efficacy of combination anti-
fungal therapy are increasingly published. A review of case 
reports of patients treated with different combinations 
of antifungal drugs noted a 70% response to combination 
therapy24. However, in most of these reports, neutropenia 
was not taken into account, and it is likely that resolution of 
neutropenia was the primary determinant of outcome. The 
largest series reported retrospectively on 37 patients who 
received combination antifungal therapy. For 27 of these 
patients, therapy consisted of a lipid formulation of AMB and 
a triazole. After 90 days of dual therapy, 41% were noted 
to have achieved a complete or partial response25, which 
is similar to the response noted with monotherapy in prior 
studies20,21. Thus, it is not clear that combination therapy 
is any more effective than monotherapy. However, if one 
is unsure of the susceptibilities of the infecting organism, 
which is the usual scenario, it seems reasonable to treat with 
a combination of drugs in the hopes of having at least one 
active drug in the treatment regimen.
We generally initiate therapy with intravenous VOR, at a 
dosage of 6 mg/kg twice on the first day, and then 4 mg/kg 
twice daily thereafter, combined with intravenous liposomal 
AMB, at a dosage of 5 mg/kg daily, which can be increased 
to 10 mg/kg daily, if needed. After the patient improves, 
we step down to oral VOR, 200-300 mg twice daily on an 
empty stomach. Voriconazole levels should be obtained 
to ensure appropriate serum concentrations are attained. 
Posaconazole can also be used as step-down therapy (but 
not initial therapy) at a dosage of 400 mg twice daily with 
food, and levels also should be obtained to ensure adequate 
absorption, which is often problematic with this drug.
Adjunctive therapy with granulocyte colony stimulat-
ing factor has been used in some centers in an attempt 
to improve the outcome of patients who remain 
neutropenic2,25. Others have infused granulocytes that were 
obtained from donors who had received granulocyte colony 
stimulating factor to stimulate higher numbers of more 
active granulocytes2.
Outcomes
Rather than the specific antifungal agent used, the most 
important factor predicting the outcome of invasive fusari-
osis is the recovery of the patient’s immune function, espe-
cially recovery from neutropenia. In several multicenter 
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and single center reports of patients who had hemato-
logical malignancies or who were hematopoietic cell trans-
plant recipients, persistent neutropenia and corticosteroid 
therapy predicted poor outcomes3,5,6,19. Mortality among 
this type of patient with disseminated fusariosis has been 
reported to be 81% to 87%2. It is almost always the case that 
if neutropenia fails to resolve, a patient with disseminated 
fusariosis will die of this infection.
Patients who are less immunosuppressed and not neu-
tropenic, such as solid organ transplant recipients, have a 
better outcome than hematopoietic cell transplant recipi-
ents. Solid organ transplant recipients tend to have local-
ized skin and subcutaneous Fusarium infections rather 
than disseminated infection, and they generally recover 
from their infection4. Immunocompetent patients who 
have localized inoculation disease have a good prognosis. 
The worst prognosis for localized infection is noted with 
keratitis due to Fusarium species; even with a corneal 
transplant, visual acuity may remain poor.
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